Johnson & Johnson (J&J) reported that the combination therapy of Lazertinib (brand name Leclaza in Korea) and Amivantamab (brand name Rybrevant) achieved impressive global sales of $141 million (approx. 200 billion KRW) in Q1 2025. Of this, $113 million (approx. 161 billion KRW) was from the U.S. market alone, accounting for 80% of total revenue. These figures mark the therapy’s first full quarter since FDA approval in August 2024.
Sales are expected to grow further following recent regulatory approvals in Korea, Japan, the UK, and the EU. The success of the combination therapy significantly contributed to J&J’s overall Q1 revenue of $21.89 billion—a 2.4% year-over-year increase—and a remarkable 237.9% jump in net income, reaching $10.99 billion.
Joaquin Duato, J&J’s CEO, highlighted the contribution of the Lazertinib + Amivantamab combo, alongside other key therapies, to the company’s growth across its pipeline. Recent Phase 3 MARIPOSA trial results presented at ELCC 2025 in Paris indicated a projected overall survival (OS) of over 48 months—more than 12 months longer than the comparator drug, Tagrisso (osimertinib).
Leclaza, developed by South Korea’s Yuhan Corporation and licensed to Janssen in 2018, was approved in Korea in 2021 as the country’s 31st domestically developed new drug.
To learn more, please click here: https://www-thebionews-net.cdn.ampproject.org/c/s/www.thebionews.net/news/articleViewAmp.html?idxno=14332
#Yuhan, #YuhanUSA, #Lazcluze, #Amivantamab, #Johnsonandjohnson #NSCLC